Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker
Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments
- Supported exchanges /
- SA /
- N1VS34.SA
Novartis AG (N1VS34 SA) stock market data APIs
R$60.26
-0.16(-0.3%)
as of November 14, 2024
Price chart is built with Anychart
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG Financial Data Overview
| 60.42 | |
| 60.26 | |
| - | |
| 60.54 | |
| 60.26 | |
| 45.323-68.54 | |
| 1 198 025 M | |
| 18.2006 | |
| 19 993 M | |
| 49 940 M | |
| 0.0211 | |
| 0.505 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'N1VS34',
Type:
'Common Stock',
Name:
'Novartis AG',
Exchange:
'SA',
CurrencyCode:
'BRL',
CurrencyName:
'Brazilian real',
CurrencySymbol:
'R$',
CountryName:
'Brazil',
CountryISO:
'BR',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - General',
}
Novartis AG Fundamental Data is available in our Financial Data APIs
- Net Revenue 49 940 M
- EBITDA 20 985 M
- Earnings Per Share 3.29
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Novartis AG Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Novartis AG End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Novartis AG latest news via APIs
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA)...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
